Rapt Therapeutics (RAPT) PT Lowered to $23 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts RAPT Hot Sheet
Price: $58.02 --0%
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins lowered the price target on Rapt Therapeutics (NASDAQ: RAPT) to $23.00 (from $27.00) while maintaining a Buy rating.
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $275 at TD Cowen
- Zimmer Biomet (ZBH) PT Raised to $102 at BMO Capital
- Snap Inc (SNAP) PT Raised to $5.75 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
